Best of ASCO - 2014 Annual Meeting



Attend this session at the
2018 ASCO Annual Meeting!

Session: Head and Neck Cancer

Type: Oral Abstract Session

Time: Sunday June 3, 8:00 AM to 11:00 AM

Location: E451

Are women with head and neck cancer undertreated?

Advanced Disease

Head and Neck Cancer

2018 ASCO Annual Meeting

Abstract No:

J Clin Oncol 36, 2018 (suppl; abstr LBA6002)

Author(s): Annie Park, Amy Albaster, Hanjie Shen, Loren K. Mell, Jed Abraham Katzel; Kaiser Permanente, Santa Clara, CA; Kaiser Permanente Division of Research, Oakland, CA; UCSD, La Jolla, CA; University of California San Diego Moores Cancer Center, La Jolla, CA

Abstract Disclosures


Background: Generalized competing event (GCE) models have been used to stratify patients with cancer according to their relative hazard for cancer death versus death from other causes. We evaluated outcomes for head and neck cancer (HNC) patients treated at Kaiser Permanente Northern California (KPNC) based on demographic data and comorbidities using a GCE model. Methods: We identified 884 HNC patients diagnosed 2000-2015 from the KPNC cancer registry, age 18-85 and stage II-IVB by AJCC 7th edition. Using the GCE proportional relative hazards model, controlling for age, sex, tumor site, and Charlson comorbidity index (CCI), we identified associations between these factors and the relative hazard for HNC-specific mortality (ω+ ratio, ‘gcerisk’ package in R). Death, disenrollment, and end of study (12/31/2016) were used as censoring events. Logistic regression models estimated the odds of receiving intensive treatment (platinum based regimen), adjusting for the same covariates plus stage, smoking, and alcohol abuse history. Results: With a median follow-up of 2.9 years, 271 patients died of cancer, and 93 of non-cancer causes. Compared to male, females were less likely to receive intensive chemotherapy (35% vs. 46%, p = 0.006) and radiation (60% vs. 70%, p = 0.008). On GCE analysis, female patients had an increased relative hazard ratio (RHR) for death from HNC vs. other causes (adjusted RHR 1.92; 95% CI 1.07-3.43), indicating they may be relatively undertreated. Conclusions: Female patients in our cohort may be undertreated in clinical practice, potentially missing the opportunity to aggressively treat their HNC. This study supports the use of a GCE methodology to objectively identify patients more likely to benefit from treatment intensification. These findings may help guide future research in health disparities.

ω+ ratio and odd ratio for select variables.

CovariateAdjusted RHR (ω+ ratio) for cancer vs. non-cancer
mortality (95% CI)
chemotherapy OR (95% CI)
OR (95% CI)
OR (95% CI)
Female1.92 (1.07-3.43)0.68 (0.48, 0.98)0.79 (0.56, 1.11)1.04 (0.72, 1.53)
CCI > = 10.75 (0.46-1.24)0.78 (0.68-0.89)0.96 (0.86-1.07)1.02 (0.91-1.15)
Age (per 10 years)0.78 (0.62-0.99)0.88 (0.75-1.02)0.90 (0.77-1.05)0.70 (0.59-0.82)

Other Abstracts in this Sub-Category:


1. Multicenter phase II trial of palbociclib, a selective cyclin dependent kinase (CDK) 4/6 inhibitor, and cetuximab in platinum-resistant HPV unrelated (-) recurrent/metastatic head and neck squamous cell carcinoma (RM HNSCC).

Meeting: 2018 ASCO Annual Meeting Abstract No: 6008 First Author: Douglas Adkins
Category: Head and Neck Cancer - Advanced Disease


2. A phase II randomized trial of nivolumab with stereotactic body radiotherapy (SBRT) versus nivolumab alone in metastatic (M1) head and neck squamous cell carcinoma (HNSCC).

Meeting: 2018 ASCO Annual Meeting Abstract No: 6009 First Author: Sean Matthew McBride
Category: Head and Neck Cancer - Advanced Disease


3. Health-related quality of life (HRQoL) of pembrolizumab (pembro) vs standard of care (SOC) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in KEYNOTE-040.

Meeting: 2018 ASCO Annual Meeting Abstract No: 6013 First Author: Ezra E.W. Cohen
Category: Head and Neck Cancer - Advanced Disease